Investor Calendar is powered by PrecisionIR, the leading webcaster of official investor relations events, and offers free access to live and archived corporate communications
Information contained in this webcast is current as of the date and time first presented. The use of pop-up blocking or firewall software may prevent you from accessing this webcast. Please temporarily disable any of these products you may have while attempting to access this event.
About The Company
InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision’s clinical-stage ophthalmic product pipeline includes AzaSite Plus™ (ISV-502) and DexaSite™ (ISV-305) for the treatment of eye infections, BromSite™ (ISV-303) for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit , please visit www.insitevision.com
.
A part of PrecisionIR Group, www.PrecisionIR.com
601 Moorefield Park Drive, Richmond, VA 23236
145 Cannon Street, London, EC4N 5BQ, UK (Registered in England No 2394368)
Strandvägen 7A, 114 56 Stockholm, Sweden